Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors
- 25 September 2007
- journal article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 42 (9) , 769-774
Abstract
Hyperlipidemia is a metabolic complication after liver transplantation (LT). The aim of this study was to investigate the prevalence and risk factors for developing hyperlipidemia in patients who underwent LT in the Shiraz Organ Transplantation Center. Our patients were 170 liver recipients who underwent LT from 1994 to 2006 in the Organ Transplantation Center of the Shiraz University of Medical Sciences. To perform this study we administered questionnaires, including information about age, sex, body mass index (BMI), underlying liver disease, graft type, immunosuppressive medications, and serum levels of triglycerides and cholesterol, before and 6 months after LT. Serum triglyceride and cholesterol levels were considered elevated if they were >150 mg/dl and >250 mg/dl, respectively. Data were analyzed with SPSS software. There were 108 male and 62 female patients, with a mean age of 31.4 ± 13.3 years, and the mean duration of follow-up was 25.9 ± 23.5 months. The average pretransplant serum triglyceride and cholesterol (mean of individual means) levels were 104.6 ± 73.2 and 109.5 ± 51.5 mg/dl, respectively, and the average posttransplant levels were 230.1 ± 131 and 185 ± 77 mg/dl, respectively. Six months after LT, 119 (70%) and 26 (15.3%) patients developed hypertriglyceridemia and hypercholesterolemia, respectively. Age, sex, BMI, and underlying liver disease were not predictors of hypertriglyceridemia or hypercholesterolemia (P > 0.05). Posttransplant hypertriglyceridemia was significantly more common in patients receiving tacrolimus than in those receiving cyclosporine (P = 0.040), but posttransplant hypercholesterolemia had no significant correlation with type of immune suppression (P > 0.05). Hyperlipidemia was common after LT, and hypertriglyceridemia was more common than hypercholesterolemia. Among all risk factors, tacrolimus therapy was correlated with development of hypertriglyceridemia after LT.Keywords
This publication has 29 references indexed in Scilit:
- Tacrolimus as Intervention in the Treatment of Hyperlipidemia after Liver TransplantTransplantation, 2006
- Cholesterol Absorption and Synthesis in Pediatric Kidney, Liver, and Heart Transplant RecipientsTransplantation, 2006
- Insulin resistance, LDL particle size, and LDL susceptibility to oxidation in pediatric kidney and liver recipientsKidney International, 2005
- Dyslipidemia during sirolimus therapy in patients after liver transplantationClinical Transplantation, 2004
- Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weightLiver Transplantation, 2001
- Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipientsLiver Transplantation, 2001
- Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapyLiver Transplantation and Surgery, 1999
- Hyperlipidemia in liver transplant recipients: Prevalence and risk factorsLiver Transplantation and Surgery, 1997
- HYPERLIPIDEMIA AFTER LIVER TRANSPLANTATIONTransplantation, 1996
- Lipid Abnormalities in Pediatric Hepatic Allograft RecipientsJournal of Pediatric Gastroenterology and Nutrition, 1989